Ascendis Pharma A/S (NASDAQ:ASND) Shares Up 5.9% - Here's What Happened

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) shares shot up 5.9% during trading on Monday . The company traded as high as $136.88 and last traded at $136.82. 266,899 shares were traded during trading, a decline of 35% from the average session volume of 409,644 shares. The stock had previously closed at $129.19.

Wall Street Analyst Weigh In

ASND has been the subject of several research analyst reports. Bank of America lifted their price objective on Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a "buy" rating in a research report on Monday, September 23rd. Wedbush reissued an "outperform" rating and issued a $181.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Stifel Nicolaus increased their target price on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a "buy" rating in a research note on Friday, November 15th. Oppenheimer decreased their price objective on Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating for the company in a report on Friday, November 15th. Finally, Wells Fargo & Company upped their price objective on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an "overweight" rating in a report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $192.07.

Ascendis Pharma A/S Trading Up 3.8 %

The company has a market capitalization of $8.13 billion, a PE ratio of -16.59 and a beta of 0.65. The stock's fifty day moving average is $132.77 and its two-hundred day moving average is $133.58.

Institutional Trading of Ascendis Pharma A/S

A number of large investors have recently bought and sold shares of ASND. Diversified Trust Co lifted its position in shares of Ascendis Pharma A/S by 7.4% during the 4th quarter. Diversified Trust Co now owns 45,038 shares of the biotechnology company's stock valued at $6,200,000 after buying an additional 3,114 shares during the last quarter. GAMMA Investing LLC boosted its position in Ascendis Pharma A/S by 58.0% during the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock worth $80,000 after purchasing an additional 214 shares during the period. Exome Asset Management LLC increased its stake in shares of Ascendis Pharma A/S by 119.2% in the third quarter. Exome Asset Management LLC now owns 43,849 shares of the biotechnology company's stock worth $6,547,000 after purchasing an additional 23,849 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Ascendis Pharma A/S in the third quarter valued at approximately $30,000. Finally, Frazier Life Sciences Management L.P. purchased a new stake in shares of Ascendis Pharma A/S during the 3rd quarter valued at approximately $19,908,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.